Angioslide Announces European Launch of New 300 mm SFA Treatment Device

 

September 9, 2011

September 9, 2011 — Angioslide Ltd. announced the first procedures with its new 5 x 300 mm Proteus device for treating the superficial femoral artery (SFA). The technology combines a percutaneous transluminal angioplasty (PTA) balloon and embolic capture of particles in one device. The new 5 x 300 mm size joins Angioslide's current dedicated product line solutions for the lower limbs.

Initial treatments using the new device were conducted in leading world centers, Parkkrankenhaus Leipzig and Herzzentrum Bad Krozingen, located in Germany. The technology makes it possible to treat lesions up to 300 mm with one device, while providing an immediate solution for embolic capture.

"Angioslide's breakthrough technology, now available also in 300 mm length as well, is a unique solution for lesions with high level of embolic material, including chronic total occlusions (CTO), in stent-restenosis, thrombus containing lesions and post atherectomy PTA," said Prof. Thomas Zeller, head of the angiology department, Heart Center Bad-Krozingen.

Prof. Dierk Scheinert, head of the department of angiology, Park-Krankenhaus Leipzig, adds, "We have been using the Proteus product line as part of our daily practice for a few years, and are working closely with the Angioslide team. I welcome the release of the 5 x 300 mm. We can now use one device to treat patients with SFA diseases, which facilitates the procedural flow and makes the intervention cost-effective."

There is a growing need for expanding the current interventional “tool box” to accommodate procedures designed specifically to treat long and diffuse lesions in a quick and effective manner. This need stems from the increase in life expectancy, diabetes prevalence, and number of high-risk patients, together with the shift toward an "endovascular-first" approach as a preferred procedure over surgical revascularization.

The Proteus 5X300 mm is currently released for the European market only. It is undergoing an evaluation regulatory process with the U.S. Food and Drug Administration (FDA).

For more information: www.angioslide.com

The content of this field is kept private and will not be shown publicly.
Type the characters you see in this picture. (verify using audio)
Type the characters you see in the picture above; if you can't read them, submit the form and a new image will be generated. Not case sensitive.